INTRODUCTION
Atrial fibrillation (AF) is one of the most common heart diseases, affecting 3 to 6 million populations in the United States, almost 30 million people worldwide, which is expected to reach 50 million peoples world wide in 2050 [14] . Patients with AF carry a higher risk of adverse cardiovascular events and reduced survival [5, 6] . Incidence of AF increases with age. At the same time, aging population is likely to develop other chronic diseases and one of them is endstage liver disease or cirrhosis [79] . This treatment of cirrhosis comprises of multidisciplinary approach ranging from very simple, symptomatic treatment with diuretic or treatment of primary cause, down the road to the most advanced treatment; liver transplantation [1013] . Liver transplantation is the treatment of choice for endstage liver diseases [10, 13] . In 2017, around 8000 patients all over the United State suffered from end stage liver disease receiving liver transplantation and the number trends to increase 3% to 5% annually in the past 20 years along with the excellent outcomes with almost 95% survival rate at 1year postprocedure and some patients could live even more than 30 years after liver transplantation [1417] . Recent advances in basic and clinical sciences, including surgical technique, immunosuppressive therapy and postoperative suppor tive care, have led to the substantial improvement in quality of life and survival after liver transplantation [18, 19] . In addition, higher risk patients tend to receive trans plantation in a higher proportion than they did before. In the view of higher risk patients, they tend to carry the risk factors that accompany with older age such as cardiovascular diseases.
In transplant centers, AF and liver transplanta tion are entities that we commonly encounter in the practice [2023] . However, the occurrence rates of preexi sting AF and AF following liver transplantation as well as clinical outcomes of liver transplant patients with AF remain unclear [2031] . Thus, we conduct this meta analysis: (1) to assess prevalence of preexisting AF and/or incidence of AF following liver transplantation, and the trends of patient's outcomes overtime; and (2) to evaluate impact of preexisting AF and postoperative AF on patient outcomes following liver transplantation.
MATERIALS AND METHODS

Search strategy and literature review
We registered this systematic review protocol with International Prospective Register of Systematic Re views, No. CRD42018093644 (PROSPERO). We cond ucted a systematic literature search of EMBASE (be tween January 1988 and March 2018), Ovid MEDLINE (between January 1946 and March 2018), and the Cochrane Database of Systematic Reviews (from data base inception to March 2018): (1) to estimate preva lence of preexisting AF and/or incidence of AF following liver transplantation; and (2) to evaluate impact of preexisting AF and postoperative AF on patient outcomes following liver transplantation. Ronpichai Chokesuwattanaskul and Charat Thongprayoon, two investigators, independently performed the syste matic literature review using the search strategy that consolidated the terms of "liver" OR "hepatic" AND "transplant" OR "transplantation" AND "atrial fibrillation", described in online supplementary data 1. No language restriction was implemented. We followed the Stren gthening the Reporting of Observational Studies in Epidemiology (STROBE) [32] and the Preferred Report ing Items for Systematic Reviews and MetaAnalysis (PRISMA) statement [33] .
Study selection
Our inclusion criteria comprised: (1) clinical trials or observational studies such as cohort, crosssectional, or casecontrol studies; (2) available data on preva lence of preexisting AF or incidence of AF following liver transplantation or outcomes of liver transplant recipients with AF; and (3) available data on prevalence, incidence, odds ratios (OR), hazard ratios, or relative risks. Re trieved articles were individually reviewed for eligibility by the two investigators as mentioned prior. Inclusion was not restricted by the size of study. Contrarieties were discussed and solved through joint agreement.
We used NewcastleOttawa quality assessment scale to assess the quality of study for cohort and casecontrol studies [34] , as shown in Table 1 .
Data items and data collection process
We used a structured information collecting form to collect the data from individual article including last name of the first investigator, title, year of publication, country that the research was carried out, baseline characteristics of liver transplant patients, processes utilized to diagnose AF, prevalence of preexisting AF, incidence of postoperative AF, patient outcomes follow ing liver transplantation.
Statistical analysis
We used Comprehensive MetaAnalysis Version 3.3.070 software (Biostat Inc., Englewood, NJ, United States) for all analyses. Estimated prevalence, incidence and estimated risks from each study were incorporated by the randomeffect, generic inversevariance approach of DerSimonian and Laird [35] . of 76%100% indicate high heterogeneity [36] . Egger test was used to evaluate publication bias [37] .
RESULTS
Study selection and characteristics
Applying our search strategy, 121 potential studies were selected. Following the elimination of 83 studies (title and abstract clearly not meeting inclusion criteria due to study design, type of study, patient popula tion or reported outcomes), 38 studies were included for complete examination. After the complete review, twenty articles were omitted because the outcome of interest was not provided and six articles were excluded since they were descriptive studies without data of interest. Hence, we included 12 articles [2031] into the final analysis including 9 cohort studies [20, 2224, 2630] and 3 casecontrol studies [21, 25, 31] with 38586 liver transplant recipients were enrolled, as demonstrated in Figure 1 . Study characteristics and quality appraisal of studies are shown in Table 1 [2031]
.
Prevalence of pre-existing AF and incidence of AF following liver transplantation Figure   3 ). When analysis was performed based on type of study, the pooled estimated incidence of AF following liver transplantation was 9.4% (95%CI: 5.5%15.6%, 
Outcomes of liver transplant recipients with AF
Data on the association between preexisting AF and the risk of mortality were limited in two studies [20, 21] . Fouad et al [24] VanWagner et al [25] Nicalau-Raducu et al [26] Josefsson et al [27] Country [20] Bargehr et al [21] Xia et al [22] Piazza et al [23] Country The pooled OR of mortality among liver transplant recipients was 2.34 (95%CI: 1.105.00, I 2 = 45%).
In addition, preexisting AF is associated with posto perative cardiovascular complications among liver tran splant recipients (3 studies [21, 28, 31] ; OR: 5.15, 95%CI: 2.679.92, I 2 = 64%). New onset AF is associated with poor outcomes after liver transplantation [22, 30] . Wange et al [30] demonstrated a significant association betw een incident AF and cerebrovascular events in liver transplant patients with OR of 3.80 (95%CI: 1.109.50). In addition to increased mortality risk, Xia et al [22] 
Risk of bias across studies
Funnel plots, as demonstrated in Supplementary  Figures 1 and 2 , and Egger tests were conducted to assess for possibility of publication bias in analyses evaluating prevalence of preexisting AF and incidence
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October 27, 2018|Volume 10|Issue 10| WJH|www.wjgnet.com of postoperative AF in liver transplant patients, respe ctively. The graph is somewhat asymmetric and implies the possibility of publication bias towards negative studies in analysis of prevalence of preexisting AF (P = 0.01). However, we found no significant publication bias in analysis evaluating incidence of postoperative AF in liver transplant patients, P = 0.32.
DISCUSSION
In this metaanalysis, we demonstrated that end stage liver disease patients who received liver transplanta tion had a prevalence of AF of 5.6%, which was higher than prevalence of AF in general patient population of 2.5% [38] . This number of higher prevalence may imply that patients who received liver transplantation appeared to carry the higher risk profiles. In addition, our study showed the pooled incidence of postliver transplant AF of 8.5%, which is lower incidence, when compared to those patients who underwent heart tran splantation (incidence of AF up to 40%) [3944] or other openheart surgeries (incidence of AF up to 50%) [5, 45, 46] . VanWagner et al [28] VanWagner et al [31] VanWagner et al [29] Wange et al This mitigated number of incidence of postoperative AF in liver transplantation could be explained by the use of intensive postoperative hemodynamic care and, immunosuppressive therapy, the surgical technique, and not physically direct impact to the heart [2831] . In general population, AF can put the patients at higher mortality risk, compared to those without AF [47] . In addition to mortality risk, our study also revealed the association of preexisting AF and incident AF with poor clinical outcomes following liver transplantation. New onset AF following liver transplantation is also associated with posttransplant acute kidney injury, cerebrovascular events, and increased risk of graft failure among liver transplant recipients. There are several mechanisms that put the liver transplant patients with AF at higher risk of postoperative morbidity and mortality compared Potentially relevant articles identified from search of MEDLINE, EMBASE, and cochrane database of systematic reviews (n = 121) to those without AF [24, 48] . Patients with AF reflect that they are frail and have already been at higher risk profiles accompanying with other cardiovascular risks (left ventricular hypertrophy, heart failure, stroke, etc.) at the time even before liver transplantation, so that they will inevitably develop higher complication rates at postoperative period [21, 49, 50] . Furthermore, AF itself plays a critical role as marker of underlying heart diseases that make patients vulnerable to perioperative hemodynamic challenges [51, 52] . There are also several mechanisms explained why liver transplantation promotes the occurrence of AF dur ing postoperative period ( Figure 6 ). Firstly, conventional postoperative hemodynamic challenge could provoke AF through hemodynamic instability or inotropic admi nistration [50] . Also, some preexisting liver diseases, such as nonalcoholic fatty liver disease (NAFLD), share a common risk factor, that is diabetes and obesity, with the AF patients [53] . In addition, NAFLD could also occur as de novo after liver transplantation and subsequently enhances the postoperative complications, contributed by systematic inflammatory mechanism [5456] . Further more, immunosuppressive therapy increases the risk to develop insulin resistance which eventually leads to metabolic syndrome [57] . Various kind of cirrhosis specific heart diseases, such as a wellknown entity called congestive hepatopathy, prior to transplantation play a substantial arrhythmogenesis role as a substrate for pathogenesis of AF [50, 58] . Various underlying medical problems including AF would, in the future, be used to identify highrisk patient population that needs to be optimized the treatment to achieve higher outcome after liver transplantation.
Leading cause of long term mortality in patients with liver transplantation is cardiovascular complica tions which, other than AF, include heart failure and myocardial infarction. These complications are pre dominantly driven by the development of metabolic syndrome after liver transplantation. However, this topic of interest is beyond the scope of our study and could be explained elsewhere [50] . More or less, these cardiovascular complications were also considered as potential risk modification strategy that should not be overlooked. Our study has noteworthy limitations. Firstly, an inconsistent in definition, for an example how to define the timing of AF as an early or late onset, among the different studies preclude to draw the generalized conclusion. Such this limitation, data use needs tailoring to the individual patient. Secondly, duration of follow up during the postoperative period by some study prospectively monitored a cardiovas cular event for just 30 d posttransplantation, which this time frame does not long enough to reveal the longterm morbidity and mortality outcome. However, with the potential of higher morbidity and mortality in liver transplant patients with AF by our metaanalysis, future studies, preferable with populationbased or national database studies, are required to discover whether focused AF cares for liver transplanted pa tients can improve patient outcomes after liver trans plantation. Finally, since our study is a metaanalysis of observational studies, it could entirely prove associa tion, but could not demonstrate a causeeffect (causal) relationship, between liver transplantation and AF.
In conclusion, our study demonstrated the actual prevalence of preexisting AF in patient underwent liver transplantation, incidence of AF postliver transplan tation. Our study also highlighted the association of AF with higher morbidity and mortality among liver transplant recipients. Further welldesigned studies are needed to explore the impact of AF in liver tran splant patients, which we strongly believe that AF management, specified to liver transplant patients, would be an important strategy to augment standard
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ARTICLE HIGHLIGHTS
Research background
Among liver transplant patients with atrial fibrillation (AF), there are lacks of data about incidence, prevalence and prognosis of AF in this specific group of patients. In spite of improvement of liver transplant care to the point of achieving almost 90% of 1-year survival rate, outcomes of liver transplantation related to AF remain unclear.
Research motivation
With excellent results of liver transplantation in term of survival, current indications of the transplantation have been extending into higher risk candidates due to higher amount of donors and more advanced treatment, which include preoperative preparation, surgical technique, immunosuppressive therapy and post-transplantation care. The high-risk liver transplant candidates tend to experience the adverse effects throughout perioperative period and worse outcomes, compared to those with less comorbidity. AF is one of the most common cardiac rhythm abnormalities and its prevalence increases with older age and higher comorbidities. Therefore, a number of patients with AF who received liver transplantation would definitely increase.
Research objectives
To examine outcomes of liver transplant recipients with AF, we performed this meta-analysis: (1) to assess prevalence of pre-existing AF and/or incidence of AF following liver transplantation, and the trends of patient's outcomes overtime; and (2) to evaluate impact of pre-existing AF and post-operative AF on patient outcomes following liver transplantation. Innovations and breakthroughs.
Research methods
We conducted a systematic literature search of EMBASE, Ovid MEDLINE, and the Cochrane Database (from database inception to March 2018): (1) to estimate prevalence of pre-existing AF and/or incidence of AF following liver transplantation; and (2) to evaluate impact of pre-existing AF and post-operative AF on patient outcomes following liver transplantation. Estimated prevalence, incidence and estimated risks from each study were incorporated by the random-effect, generic inverse-variance approach of DerSimonian and Laird. 
Research results
There were significant associations of AF with worse clinical outcomes following liver transplantation including 2.3-fold higher risk of death and 5.1-fold higher risk of postoperative cardiovascular complications, and poor clinical outcomes such as stroke, acute kidney injury and graft failure. We also showed the incidence of postoperative AF, namely 8.5%, consistently across different type of studies without the change overtime by meta-regression.
Research conclusions
The overall estimated prevalence of pre-existing AF and incidence of AF following liver transplantation are 5.4% and 8.5%, respectively. Incidence of AF following liver transplant does not seem to decrease overtime. Pre-existing AF and new-onset AF are potentially associated with poor clinical outcomes post liver transplantation.
Research perspectives
This systematic review confirmed higher risks of death and postoperative complications in liver transplant patients with AF. Our findings indicate that AF may be an independent predictor for worse clinical outcomes following liver transplantation.
